{"product_id":"tirzepatide-peptide-intelligence-monograph","title":"Tirzepatide — Peptide Intelligence Monograph","description":"\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003e\u003cstrong\u003eShort description\u003c\/strong\u003e\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe Evidence Behind the Hype.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA physician-reviewed, evidence-based examination of tirzepatide from the Founder’s Institute of Medicine \u0026amp; Education.\u003c\/p\u003e\n\u003cp\u003eThis digital monograph separates findings supported by randomized human clinical trials and regulatory review from emerging research, mechanistic extrapolation, off-label claims, and questions that remain unanswered.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFull product description\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTirzepatide has transformed the conversation surrounding metabolic disease and weight management. But what does the evidence actually show?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist supported by an unusually substantial body of human clinical research.\u003c\/p\u003e\n\u003cp\u003eUnlike many compounds discussed in the peptide marketplace, tirzepatide has undergone large randomized controlled trials and regulatory evaluation. Yet its rapid adoption has also generated claims that extend well beyond what has been firmly established.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003eTirzepatide Peptide Intelligence Monograph\u003c\/strong\u003e examines the evidence systematically—distinguishing demonstrated clinical outcomes from mechanistic hypotheses, emerging applications, extrapolation, and promotional claims.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eInside the monograph:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTirzepatide pharmacology and dual GIP\/GLP-1 receptor activity\u003c\/li\u003e\n\u003cli\u003eHuman randomized clinical-trial evidence\u003c\/li\u003e\n\u003cli\u003eGlycemic control and metabolic outcomes\u003c\/li\u003e\n\u003cli\u003eWeight-loss and body-composition evidence\u003c\/li\u003e\n\u003cli\u003eCardiometabolic outcomes and risk factors\u003c\/li\u003e\n\u003cli\u003eSafety, tolerability, and adverse-event evidence\u003c\/li\u003e\n\u003cli\u003eRegulatory status and approved uses\u003c\/li\u003e\n\u003cli\u003eEmerging research and proposed applications\u003c\/li\u003e\n\u003cli\u003eLimitations, uncertainties, and important evidence gaps\u003c\/li\u003e\n\u003cli\u003eClaim-by-claim \u003cstrong\u003eFIPES evidence grading\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eWhat we know, what we do not know, and what research is still needed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003ePhysician reviewed. Evidence graded. No protocols. No dosing instructions. No promotional claims.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis publication is intended for education and scientific evidence review. It is not medical advice and does not recommend or instruct the use of tirzepatide.\u003c\/p\u003e","brand":"Founder's Institute of Medicine \u0026 Education","offers":[{"title":"Default Title","offer_id":45379680370870,"sku":null,"price":24.95,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0736\/0990\/4310\/files\/ChatGPTImageAug26_2026_08_37_13PM_3c0ed3f5-e912-43bc-aa65-fd69e23686ec.png?v=1787808151","url":"https:\/\/foundersinstitutemed.org\/products\/tirzepatide-peptide-intelligence-monograph","provider":"Founder's Institute of Medicine \u0026 Education","version":"1.0","type":"link"}